SP

Sunita Pratapsinh Nangare

Active Director Director DIN 10639003
DIN 10639003 First appointment May 2024 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since May 2024
Shareholding value β€’β€’β€’β€’ Premium profile

About Sunita Pratapsinh Nangare

Data last updated:

Sunita Pratapsinh Nangare is a Director at Cliquemed Pharmaceuticals Private Limited (since 2024). The company operates in Pharma.

DIN 10639003
Primary Designation Director
Industry Pharma
First Appointment 22 May 2024
Oldest Company Age 2 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director22 May 20242024Active

Board colleagues of Sunita Pratapsinh Nangare

Directorship timeline

Open interactive timeline →
Cliquemed Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Sunita Pratapsinh Nangare

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Sunita Pratapsinh Nangare

Sunita Pratapsinh Nangare currently holds 1 directorship: Cliquemed Pharmaceuticals Private Limited (Director, since 22 May 2024).

Sunita Pratapsinh Nangare was first appointed on 22 May 2024 as Director at Cliquemed Pharmaceuticals Private Limited.

The current boards of Sunita Pratapsinh Nangare's companies include Namrata Suhas Mundhe (Cliquemed Pharmaceuticals Private Limited), Smita Ravindra Kadav (Cliquemed Pharmaceuticals Private Limited), Sushma Sandesh Kamble (Cliquemed Pharmaceuticals Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available